Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ... with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

and Pfizer’s Elrexfio (elranatamab), which have both been cleared by the FDA for relapsed or refractory multiple myeloma. The top-line efficacy data with Regeneron’s drug looks a little ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

"Despite treatment advances, patients with multiple myeloma inevitably ... and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...